A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

@article{vanLeeuwen2003ART,
  title={A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients},
  author={Remko van Leeuwen and Christine Katlama and Robert Leo Murphy and Kathleen E. Squires and Josep Mar{\'i}a Gatell and Andrej Horban and Bonaventura Clotet and Shlomo Staszewski and Arne van Eeden and Nathan Clumeck and Mauro Moroni and Andrew T. Pavia and Reinhold Ernst Schmidt and J. Gonz{\'a}lez-lahoz and Julio S. G. Montaner and Francisco Antunes and Robert J. Van Gulick and D{\'e}nes B{\'a}nhegyi and Marc van der Valk and Peter Reiss and Liesbeth van Weert and Frank van Leth and Victoria A. Johnson and Jean Pierre Sommadossi and Joep M. A. Lange},
  journal={AIDS},
  year={2003},
  volume={17},
  pages={987-999}
}
Objective: To compare one protease inhibitor (PI)-based and two PI-sparing antiretroviral therapy regimens. Methods: International, open label, randomized study of antiretroviral drug-naive patients, with CD4 lymphocyte counts ⩾ 200 × 106 cells/l and plasma HIV-1 RNA levels > 500 copies/ml. Treatment assignment to stavudine and didanosine plus indinavir or nevirapine or lamivudine. Primary study endpoint was the percentage of patients with plasma HIV-1 RNA levels < 500 copies/ml after 48 weeks… Expand
Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine
TLDR
All treatment regimens demonstrated excellent 96-week results, and secondary analyses favored the NNRTI regimen over the PI and NRTI regimens. Expand
Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals
TLDR
IDV/RTV 400/100 mg twice daily is an effective and safe first-line antiretroviral therapy and the simplicity and the low cost is of major interest particularly in countries with limited resources. Expand
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine
TLDR
The A/S/D regimen had a low efficacy and a high frequency of adverse events and cannot be recommended and had a particularly poor outcome in patients with higher viral load and AIDS at baseline. Expand
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults
TLDR
NNRTI and BPI-containing regimens offer superior virologic suppression over 48 weeks, supporting existing guidelines for the choice of initial ART and identifying the predictors of responses. Expand
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
TLDR
In this trial of the initial treatment of HIV-1 infection, the triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to a regimen containing efavirenz and two or three nucleosides. Expand
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
TLDR
In treatment-experienced patients with NNRTI resistance, treatment with TMC 125 achieved better virological suppression at week 24 than did placebo, and the safety and tolerability profile of TMC125 was generally comparable with placebo. Expand
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
TLDR
Antiretroviral therapy with nevirapine or efavirenz showed similar efficacy, so triple-drug regimens with either NNRTI are valid for first-line treatment, there are, however, differences in safety profiles. Expand
Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients
TLDR
These findings demonstrate the safety and efficacy of the ATV300/RTV regimen and confirm the efficacy of ATV400 in an ARV-naive patient population. Expand
Higher Virological Effectiveness of NNRTI-Based Antiretroviral Regimens Containing Nevirapine or Efavirenz Compared to a Triple NRTI Regimen As Initial Therapy in HIV-1-Infected Adults
TLDR
In a routine clinical care setting, initial antiretroviral treatment with an NNRTI (nevirapine or efavirenz) plus zidovudine and lamivudine was virologically superior and safer than a 3-N RTI therapy (abacavir with the same NRTI backbone). Expand
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
TLDR
Initial antiretroviral therapy including NVP or EFV is effective in patients with an advanced HIV-1 infection, and a high baseline CD4 cell count is associated with the occurrence of rash in female patients using NVP. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
TLDR
Treatment with indinavir, zidovudine, and lamivudine as compared with zidvudine and lam ivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidavudine. Expand
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
TLDR
In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year. Expand
Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
TLDR
The results suggest that three drug regimens containing two NRTI with a PI, a NNRTI, or a third N RTI may provide comparable activity, and practical issues such as daily pill burden should be considered when choosing a treatment regimen. Expand
A randomized, double-blind trial comparing combinations of Nevirapine, Didanosine, and Zidovudine for HIV-infected patients: the INCAS trial
TLDR
Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied, suggesting that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance. Expand
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
TLDR
Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied, suggesting that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance. Expand
Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy
TLDR
The results demonstrate that suppression of pVL below 20 copies/ml is necessary to achieve a long-term antiretroviral response and support the need for a revision of current therapeutic guidelines for the management of HIV infection. Expand
Decrease of HIV‐1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine
TLDR
Treatment with this triple antiretroviral drug combination produced a durable and strong decrease of HIV-1 RNA burden in both plasma and lymphoid tissue. Expand
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
TLDR
In this study of antiretroviral-naive HIV-infected adults, the triple nucleoside regimen of abacavir-lamivudine-zidovudine -zidvudine was equivalent to the regimen of indinavir- LamivUDine-ZidovUDine in achieving a plasma HIV RNA level of less than 400 copies/mL at 48 weeks. Expand
The Virgo Study: Nevirapine, Didanosine and Stavudine Combination Therapy in Antiretroviral-Naive HIV-1-Infected Adults
TLDR
Combination therapy with the three reverse transcriptase (RT) inhibitors stavudine, once-daily didanosine and either once- or twice-daily nevirapine could be considered as an alternative option for first-line antiretroviral therapy. Expand
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV‐infected patients
TLDR
Nevirapine exhibits significant although transient anti-HIV activity in ZDV-pretreated patients but its use is frequently associated with a hypersensitivity reaction. Expand
...
1
2
3
4
...